LNC THERAPEUTICS
LNC Therapeutics is a microbiota-centric R&D company focused on developing gut microbiota directed drugs to treat obesity and associated cardiometabolic diseases. They aim to revolutionize obesity management through innovative therapies that act on the gut microbiota, with a strong emphasis on safety, efficacy, and long-term results. Their solutions include medical nutrition products like Stablor and microbiome-directed drugs like the Temys Project, targeting fundamental causes of obesity and metabolic disorders.
Industries
Nr. of Employees
small (1-50)
Products
Medical nutrition product (microbiome modulator)
A medical-food formulation designed to modulate the gut microbiome in overweight/obese adults; composition includes a specific blend of amino acids, milk-derived biopeptides and micronutrients paired with a controlled dietary protocol.
Gut microbiota-directed drug development program (drug pipeline)
A drug-development program aimed at generating therapeutics that restore intestinal ecosystem balance, reduce inflammation and improve gut barrier function to treat obesity-related visceral fat accumulation and related pathologies.
Medical nutrition product (microbiome modulator)
A medical-food formulation designed to modulate the gut microbiome in overweight/obese adults; composition includes a specific blend of amino acids, milk-derived biopeptides and micronutrients paired with a controlled dietary protocol.
Gut microbiota-directed drug development program (drug pipeline)
A drug-development program aimed at generating therapeutics that restore intestinal ecosystem balance, reduce inflammation and improve gut barrier function to treat obesity-related visceral fat accumulation and related pathologies.
Services
Program management of projects encompassing fundamental research, preclinical studies and clinical trials for microbiome-directed interventions.
Program management of projects encompassing fundamental research, preclinical studies and clinical trials for microbiome-directed interventions.
Expertise Areas
- Microbiome therapeutics development
- Medical nutrition formulation and clinical evaluation
- Clinical trial design and execution (randomized controlled trials)
- Microbiome sequencing and metabolomics integration
Key Technologies
- Microbial genomic sequencing (16S/shotgun)
- Metabolomics and metabolic profiling
- Dual-energy X-ray absorptiometry (DXA) for body composition
- Animal models for translational studies
News & Updates
Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy.
Variation in the human fecal microbiota has been associated with body mass index (BMI). The study explores links between fecal microbiota and abdominal adiposity, confirming the association of Christensenellaceae with lower visceral fat and lean BMI.
Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy.
Variation in the human fecal microbiota has been associated with body mass index (BMI). The study explores links between fecal microbiota and abdominal adiposity, confirming the association of Christensenellaceae with lower visceral fat and lean BMI.